HyperBranch Medical Technology Inc., Raleigh, N.C., raised $6 million in its first round of funding. The round was led by The Aurora Funds, and included H.I.G. Ventures. The funding will be used ...

HyperBranch has already commercialized a liquid eye bandage called OcuSeal. That product was licensed to medical device giant BD (NYSE:BDX), which is marketing the product outside the United States.

HyperBranch intends to file a motion pursuant to 35 U.S.C. Section 285 asking the Court to deem the case to be exceptional and award HyperBranch its attorneys’ fees and other defense costs.

October 1, 2018 - Stryker (SYK) announced today the acquisition of privately-held HyperBranch Medical Technology, Inc. for a total equity value of approximately $220 million in an all cash ...

Stryker Corporation SYK recently announced the acquisition of HyperBranch Medical Technology for a deal value of $220 million in cash. The buyout is likely to boost Stryker's core Neurotechnology ...

Stryker Corp. on Monday said it acquired venture-backed medical-device maker HyperBranch Medical Technology Inc. in an all-cash deal valued at about $220 million.

HyperBranch, founded in 2003, produces polymer-based products that can be used to seal wounds in tissues. The company employs 11 people in the Triangle.

Surgical sealant developer HyperBranch Medical Technology is raising $1M as the company moves forward on a clinical development of a sealant for use in neurosurgery.The Durham company has raised ...

Hyperbranch's OcuSeal liquid eye bandage has received a "CE Mark," which will allow the Durham company to sell the product in the European Union. Chief Executive John Conn said the CE Mark also is ...

HyperBranch’s liquid eye bandage OcuSeal was licensed to medical device giant BD (NYSE:BDX), which is marketing the product outside the United States.

HyperBranch intends to file a motion pursuant to 35 U.S.C. Section 285 asking the Court to deem the case to be exceptional and award HyperBranch its attorneys’ fees and other defense costs.